ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM
Abstract Number: 0281
ANCA in SLE: Prevalence and Predictor Factors
9:00AM-11:00AM
Abstract Number: 0257
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
9:00AM-11:00AM
Abstract Number: 0248
Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)
9:00AM-11:00AM
Abstract Number: 0242
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0280
Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application
9:00AM-11:00AM
Abstract Number: 0252
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
9:00AM-11:00AM
Abstract Number: 0260
Does Higher Quality of Care in SLE Improve Quality of Life?
9:00AM-11:00AM
Abstract Number: 0251
Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
9:00AM-11:00AM
Abstract Number: 0255
Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
9:00AM-11:00AM
Abstract Number: 0265
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
9:00AM-11:00AM
Abstract Number: 0271
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0246
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
9:00AM-11:00AM
Abstract Number: 0263
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0267
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
9:00AM-11:00AM
Abstract Number: 0259
Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
9:00AM-11:00AM
Abstract Number: 0268
Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 0277
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
9:00AM-11:00AM
Abstract Number: 0254
LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
9:00AM-11:00AM
Abstract Number: 0247
Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0250
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
9:00AM-11:00AM
Abstract Number: 0273
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
9:00AM-11:00AM
Abstract Number: 0275
Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus
9:00AM-11:00AM
Abstract Number: 0256
Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 0261
Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 0264
Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0279
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0253
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0262
SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes
9:00AM-11:00AM
Abstract Number: 0272
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
9:00AM-11:00AM
Abstract Number: 0245
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
9:00AM-11:00AM
Abstract Number: 0269
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
9:00AM-11:00AM
Abstract Number: 0266
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0270
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
9:00AM-11:00AM
Abstract Number: 0274
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
9:00AM-11:00AM
Abstract Number: 0243
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
9:00AM-11:00AM
Abstract Number: 0278
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 0276
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
9:00AM-11:00AM
Abstract Number: 0258
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
9:00AM-11:00AM
Abstract Number: 0249
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
9:00AM-11:00AM
Abstract Number: 0244
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology